Retrospective medical chart review study assessed real world treatment patterns and outcomes DUBLIN, Dec. 13, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational...
Read More
In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison DUBLIN, Ireland and LAKEWOOD, Colo. USA...
Read More
Analysis from the largest known, ongoing, retrospective, explorative, single-arm, pan-European multicenter study of ECP in heart transplant patients suggests potential for ECP in the treatment of acute cellular rejection, antibody...
Read More
Rich diversity of cutting-edge ECP science represented in Mallinckrodt’s 2021 research award Dublin, Ireland, March 19, 2021 – A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy...
Read More
DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of...
Read More